From Yahoo Finance: 2025-05-08 01:48:00

The stock market rebounded on Wednesday, with all major indices in the green as investors reacted positively to the Federal Reserve’s decision to keep interest rates unchanged. The Dow Jones rallied by 0.70 percent, the S&P 500 increased by 0.43 percent, and the Nasdaq grew by 0.27 percent.

Tempus AI, Inc. (TEM) saw its share prices skyrocket by 12.59 percent on Wednesday to finish at $58.76 apiece. This increase was attributed to an optimistic outlook guidance, offsetting a disappointing earnings performance during the past quarter. The company is targeting $1.25 billion in revenues for the consolidated Tempus and Ambry Genetics for full-year 2025, representing an 80 percent growth year-on-year.

During the first quarter, Tempus AI, Inc. (TEM) widened its net loss by 5.1 percent to $68 million from $64.7 million in the same period last year. However, revenues were higher by 75.86 percent to $255 million from $145.8 million, with Genomics contributing $193.8 million, an 88.9 percent increased contribution year-on-year.

Tempus AI, Inc. (TEM) CEO Eric Lefkofsky stated, “The business is performing well with revenues growing, margins improving, and our costs remaining in check, allowing us to demonstrate significant year-over-year operating leverage.” The company’s strategic investments in AI position them uniquely to advance diagnostics and drug development, evident in their partnership with AstraZeneca and Pathos to build the largest foundation model in oncology.

Read more: Why Tempus AI, Inc. (TEM) Skyrocketed On Wednesday